natgillin/translations-raw huggingface dataset:
The process of claim 1, wherein the silk fibroin is in the form of an aqueous solution having a pH that is about pH 4 or lower or is about pH 7.5 or higher. 
Postupak prema zahtjevu 1, gdje je fibroin svile u obliku vodene otopine čiji je pH oko pH 4 ili niži ili je oko pH 7,5 1li više.
we measured tolperisone alone and in the presence of 0.25 µM dextromethorphan, and compared the two dose-response curves (see: Table 5. 
mjerili smo sam tolperison i u prisutnosti 0,25 uM dekstrometorfana, i usporedili dvije krivulje reakcije na dozu (vidi tablicu 5.
A process according to claim 12 or claim 13 wherein step (c) comprises treating the salt form of isomer IIIb with an acid to form isomer IIIb. 
Postupak u skladu s patentnim zahtjevom 12 ili patentni zahtjev 13, naznačen time što se korak (c) sastoji u obradi solnog oblika izomera IIIb kiselinom kako bi se dobilo izomer IIIb.
Figure 2 shows a front view of the sampler shown in Figure 1; 
Slika 2 - prikazuje pogled s prednje strane na napravu za uzimanje uzorka, koja je prikazana na slici 1;
converting a medium containing a xylose source with a cell according to claim 7, which converts xylose to produce the metabolization product, optionally obtaining the metabolization product, the metabolization product being selected from lactic acid, acetic acid, succinic acid, malic acid, 1-butanol, isobutanol, 2-butanol, other alcohols, amino acids, 1,3-propanediol, ethylene, glycerol, a B-lactam antibiotic or a cephalosporin, alkanes, terpenes, isoprenoids and the precursor molecule amorphadiene of the antimalarial drug artemisinin. 
opcionalno, dobivanje produkta metabolizma, pri čemu je produkt metabolizma poželjno odabran iz grupe kemikalija na temelju biobaza, kao što je mliječna kiselina, octena kiselina, jantarna kiselina, maleinska kiselina, 1-butanol, izobutanol, 2-butanol, drugi alkoholi, aminokiseline, 1,3-propandiol, etilen, glicerol, B-laktamski antibiotik ili cefalosporin, alkani, terpeni, izoprenoidi ili prekursorska molekula amorfadiena iz antimalarijski aktivnog sastojka artemizinina, pri čemu medij poželjno sadrži dodatni izvor ugljika, posebno glukozu.
contacting said aroma fraction with an oil to remove undesired aroma compounds comprising furans, pyrroles and/or thiols; 
stavljanja u kontakt navedene aromatične frakcija s uljem kako bi se uklonilo nepoželjne aromatične spojeve, koji uključuju furane, pirole i/ili tiole;
This cell line is able to produce IFN-Y in response to human IL-18 plus human TNF-a in a dose-dependent manner, r-hIL-18BP thereby suppressing the production of IFN-Y. 
Ova stanična linija sposobna je proizvoditi INF-y kao odgovor na ljudski IL-18 uz prisutnost TNF-a i to na način koji je ovisan o dozi, a gdje r-hIL-18BP suprimira proizvodnju INF-y.
a light chain comprising a light chain variable domain comprising the sequence of SEQ ID NO:188 and a heavy chain comprising a heavy chain variable domain comprising the sequence of SEQ ID NO: 189; or 
varijabilnu domenu jakog lanca koja sadrži HVR1-H1, HVR-H2 i HVR-H3 od SEQ ID NO:164-166 i varijabilnu domenu slabog lanca koja sadrži HVR-L1, HVR-L2 i HVR-L3 od SEQ ID NO:156-158; ili
A method according to claim 1 which comprises the further step: decoding, in a receiver of a device, the payload data transmitted at the higher data rate indicated within the frame information portion, using a clock signal recovered from the data sent at a higher data rate. 
Postupak prema zahtjevu 1, naznačen time, da nadalje obuhvaća dodatni korak: dekodiranje, u jednom prijamniku od jednog uređaja, skupova korisničkih informacija (36) koji su preneseni uz veću podatkovnu brzinu, prikazanom unutar odsjeka informacijskog okvira (34), korištenjem taktnog signala koji se obnovljen dobio iz podataka koji su poslani uz veću podatkovnu brzinu.
The pharmaceutical composition for use according to claim 1 or 2, wherein the pharmaceutical composition comprises the PRG4 in the therapeutically effective concentration of 50-500 µg/mL. 
Farmaceutski oblik za uporabu prema zahtjevu 1 ili 2, gdje farmaceutski oblik sadrži PRG4 u terapijski učinkovitoj koncentraciji od 50-500 ug/mL.
When the mouthpiece cover is in the second position, it leans on the protruding part on the other end of the rotational path and one dose of the medicament in dry powder form is prepared for inhalation upon the actuation of the device. 
- u drugom položaju se poklopac nastavka za usta nalazi na dijelovima koji strše (23b, 24b) na drugom kraju rotacijske putanje i jedna doza suhog praškastog lijeka je spremna za inhaliranje zbog aktiviranja uređaja. 3.
A compound of claim 1, represented by formula (XIV) or (XVI): wherein G1, G2, n, m, p, B, C, R1, R2, R3, and R8 are as defined in claim 1. 
(Rz)p Formula XIV Formula XVI pri čemu Gi, G2, 1, m, p, B, C, Ry, Ro, Ra, 1 Rz su kako je definirano u zahtjevu 1.
More specifically, the composition according to the invention has sustained in-vitro release of at least 45% after 8 hours. 
Farmaceutski pripravak u skladu sa bilo kojim od zahtjeva 1 do 9 koji ima in vitro oslobađanje od najmanje 45% nakon $ sati.
Preferably the immunogenic composition is as herein defined. There is also provided the use of an influenza virus or antigenic preparation thereof and an oil-in-water emulsion adjuvant in the preparation of an immunogenic composition as herein defined for vaccination of human elderly against influenza. 
Upotreba virusa influence ili njegovog antigenskog pripravka i emulzije ulja u vodi kao adjuvansa u pripravi imunogenog pripravka za cijepljenje čovjeka starijeg od 65 godina i više protiv influence, naznačena time što navedena emulzija ulja u vodi sadrži ulje koje se može metabolizirati, a-tokoferol i emulgator.
Accelerated conditions were used for stability testing. 
Za ispitivanje stabilnosti korišteni su pojačani uvjeti.
exposing a mouse according to any one of claims 1 to 10 or 17 to an antigen; allowing the mouse to develop an immune response to the antigen; and isolating from the mouse of (b) an antibody that specifically recognizes the antigen, or isolating from the mouse of (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, wherein the antibody comprises a heavy chain derived from a human VH gene segment, a human DH gene segment, a human JH gene segment and a mouse CH gene and a light chain derived from a human Vλ gene segment, a human Jλ gene segment and a mouse Ck gene. 
(b) puštanja miša da razvije imunološki odgovor na antigen; i (c) izoliranja iz miša prema (b) antitijela koje specifično prepoznaje antigen, ili izoliranja iz miša prema (b) stanice koja sadrži imunoglobulinsku domenu koja specifično prepoznaje antigen, naznačeno time, što antitijelo sadrži teški lanac dobiven iz humanog segmenta gena V,, humanog segmenta gena D;,, humanog segmenta gena Ig i mišjeg gena Cry te laki lanac dobiven iz humanog segmenta gena VA, humanog segmenta gena JA i mišjeg gena CK.
arene represents a benzene, or a benzene substituted with from 1 to 6 linear or branched C1-C6 alkyl groups, or mixtures thereof; X represents a halogen atom selected from chlorine, bromine, fluorine, iodine; 
aren predstavlja benzen, ili benzen supstituiran s od 1 do 6 linearnih ili razgranatih C1-C6 alkil grupa, ili njihove smjese; X predstavlja halogeni atom odabran od klora, broma, fluora, joda;
The compound as recited in Claim 1, comprising the administration of another therapeutic agent. 
VBPISili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je spoj VBP15.
A multi-room building, comprising a corridor extending horizontally, and at least a first part of a building according to claim 17 arranged on a first side of said corridor, and a second part of a building according to claim 17 arranged on the opposite side of said corridor, wherein said second part of the building is aligned with the first part of the building. A building constructed in accordance with a method as claimed in any one of claims 1-16, respectively. 
Postupak sukladno zahtjevu 17 ili 18, nadalje sadrži korak proširenja navedene višesobne građevine u horizontalnom smjeru na način da svaki dio građevine, omogućen sukladno postupku iz bilo kojeg od zahtjeva 1 do 16, s prve strane hodnika je poravnat s odgovarajućim dijelom građevine na suprotnoj strani hodnika.
As a main component of the extracellular matrix HA is present in all parts of the body. 
Kao glavna komponenta izvanstaničnog matriksa HA je prisutan u svim dijelovima tijela.
The composition according to any of claims 1-5, wherein the one or more surfactants are selected from the group consisting of a C12-14 alcohol polyethylene glycol ether mixture such as a mixture of fatty alcohols with 9 mol ethylene oxide and fatty alcohols with 3 mol ethylene oxide; and iso-C12-14 alcohol ethoxylates such as iso-C13 alcohol ethoxylate and combinations thereof. 
Pripravak prema bilo kojem od zahtjeva 1-5, naznačen time da se jedan ili više surfaktanata biraju iz skupine koja sadrži smjesu C12-14 alkohola polietilen glikol etera kao što je smjesa masnih alkohola s 9 mol etilen oksida i masnih alkohola s 3 mol etilen oksida; te izo-C12-14 alkohol etoksilate kao što je izo-C13 alkohol etoksilat i njihove kombinacije.
The organic phase was then diluted with N-methyl pyrrolidinone (460mL) and the dichloromethane removed by stirring at 40°C under vacuum for 2hrs. 
Organsku fazu se zatim razrijedi N-metilpirolidinonom (460 ml), a diklormetan ukloni miješanjem 2 sata na 40 *C u vakuumu.
Composition according to claim 1 or 2, wherein the hydroxyhydrocarbyl residue comprises at least two hydroxyl groups. 
Pripravak prema zahtjevu 1 ili 2, naznačen time, što hidroksihidrokarbilni ostatak sadržava najmanje dvije hidroksilne skupine.
This ratio influences on the price of preservative solution and its resistance against copper leaching. 
Ovaj omjer utječe na cijenu konzervansa i njegovu otpornost na ispiranje bakra.
The method of claim 9, wherein the host cell is a dendritic cell, a monocyte or a macrophage. 
Primjena prema zahtjevu 39, pri čemu je stanica domaćin stanica koja prezentira antigen, a posebno dentritska stanica, monocit ili makrofag.
The supernatant is discarded and the membrane pellet resuspended in homogenisation buffer (75 mM Tris-OH, 12.5 mM MgCl2, 0.3 mM EDTA, 1 mM EGTA, 250 mM Sucrose, 1 x Complete™ tablet. 
Otopina iznad taloga je odbačena 1 talog membrana je ponovno suspendiran u puferu za homogenizaciju (75 mM Tris-OH, 12,5 mM MgCk, 0,3 mM EDTA, 1 mM EGTA, 250 mM saharoze, 1 x tableta Complete!".
The aqueous phase was separated and freeze-dried. The crude product was purified by preparative HPLC (column Vydac 218TP, C18, 250×50 mm, flow 60 ml/min, gradient 10% to 70% CH3CN/0.1% TFA in 120 min, detector UV at 240 nm, collection 55 to 75 min) thereby affording intermediate (11′) which was freeze-dried as a white solid. 
Sirovi produkt je čišćen preparativnom HPLC (kolona Vydac 21 &8TP, C18, 250x50 mm, protok 60 mL/min, gradijent 10% do 70% CH;ON/0.1% TEA u 120 min, detektor UV pri 240 nm, sakupljeno od 55 do 75 min) i time je dobiven međuprodukt (11') koji je liofiliziran kao bijela krutina.
The apparatus according to claim 7, wherein said transmission device (11) further comprises a central control unit (22), in particular a central processing unit. 
Uređaj prema zahiljevu 7, naznačen time, da spomenuti prijenosni uređaj (11) nadalje obuhvaća centralnu upravljačku jedinicu (22), poglavito centralnu jedinicu za obradu podataka.
A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se + iz spoja ili farmaceutski prihvatljive soli iz patentnog zahtjeva 1 i najmanje jednog farmaceutski prihvatljivog nosača.
the heavy chain complementarity determining region HCDR1 having the amino acid sequence of SEQ ID NO: 2315, the HCDR2 having the amino acid sequence of SEQ ID NO: 2316 and the HCDR3 having the amino acid sequence of SEQ ID NO: 2317, and the light chain complementarity determining region LCDR1 having the amino acid sequence of SEQ ID NO: 2318, the LCDR2 having the amino acid sequence of SEQ ID NO: 2319 and the LCDR3 having the amino acid sequence of SEQ ID NO: 2320; and 
HCDR1 regiona za određivanje komplementarnosti teškog lanca koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2315, HCDR2 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2316 i HCDR3 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2317 i LCDR1 regije za određivanje komplementarnosti lakog lanca koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2318, LCDR2 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2319 i LCDR3 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2320; i
Suitable penetration enhancers include salycilic acid, urea, monothioglycerol, N-acethylcysteine, ethyl acetate, dimethyl sulphoxide (DMSO), dimethylacetamide and the penetration enhancers disclosed in WO 99/39680. 
Pogodni pojačivači penetracije uključuju salicilnu kiselinu, ureu, monotioglicerol, N-acetilcistein, etilni acetat, dimetilni sulfoksid (DMSO), dimetilacetamid i pojačivače penetracije patentirane u WO 99/39680.
Both test compounds were stored for six months at +37°C and at a relative humidity of 80%. 
Oba test spoja su skladištena šest mjeseci na +37 "C 1 na Telativnoj vlažnosti od 80 %.
As described above and shown in the Figures the container 2 is placed in an upright position with the outlet 9 facing downwards, i.e. 
Kako je gore opisano i kako je prikazano na slikama, spremnik 2 je postavljen u uspravnom položaju s izlazom 9 koji gleda prema dolje, tj.
A compound of claim 1 or 14, wherein R1, when present, is selected from the group consisting of -CO2H or C1-4 alkyl, optionally substituted with -OH, -ORm, -S(O)2Rm, -CO2H and -CO2Rm. 
Spoj u skladu s patentnim zahtjevom 1 ili 14, naznačen time, da je R1, kada je prisutan, odabran iz skupine koju čine -CO2H ili C1-4 alkil, po izboru supstituiran sa -OH, -ORm, -S(O)2Rm, -CO2H i -CO2Rm.
3-(4-decylbenzylamino)cyclopentane-1,1-dicarboxylic acid as well as their enantiomers, diastereoisomers, mixtures thereof, free forms and pharmaceutically acceptable salts, hydrates, solvates and esters. 
Spoj prema bilo kojem od prethodnih patentnih zahtjeva, kojeg se bira iz skupine koju čine: 3-(4-nonilbenzilamino)ciklopentan-1,1-dikarboksilna kiselina 3-(4-decilbenzilamino)ciklopentan-1,1-dikarboksilna kiselina kao 1 njihovi enantiomeri, dijastereoizomeri, njihove smjese, slobodni oblici i farmaceutski prihvatljive soli, hidrati, te solvati.
The oil was dissolved in carbon disulfide (360 ml.) and the resulting solution added to a well stirred suspension of AlCl3 (1.5 kg., 12.5 moles) in carbon disulfide (1.20 1.), with the mixture held below 8°C. during the addition period, forming a brown mass. 
Ulje se otopi u ugljendisulfidu (360 ml.) i dobivena otopina doda se na dobro miješanu suspenziju AlC1 (1.5 kg., 12.5 molova) u ugljendisulfidu (1.20 1), pri čemu se smjesa drži ispod 8"C. za vrijeme perioda dodavanja, tako da se formira mrka masa.
The apparatus according to claim 1, wherein said at least one metal duct is made of ferromagnetic material. 
Aparat u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je navedena najmanje jedna metalna cijev (2) načinjena od feromagnetskog materijala.
Results (Figure 9) indicate that rats treated with rapamycin displayed significantly increased levels of cholesterol relative to a vehicle control group, while cholesterol levels in the 42-O-(D-fructosylcarbonyl)rapamycin group were significantly lower (p < 0.01) than in the rapamycin group and not significantly different than the vehicle. 
Rezultati (slika 9) pokazuju da štakori tretirani rapamicinom pokazuju značajno povišene razine kolesterola u usporedbi s kontrolnom grupom, dok su razine kolesterola u grupi 42-O-(D-fruktozilkarbonil)rapamicina bile značajno niže (p < 0,01) nego u rapamicinskoj grupi, a ne značajno različite od nosača.
To the yellow mixture 525 mL of water was added and stirred overnight. 
U žutu smjesu doda se 525 ml vode, te miješa preko noći.
R2, R3 and R4 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl; 
, R3 i R4 su svaki neovisno vodik, halogen, hidroksi, niži alkil, niži alkoksi ili niži alkenil, pri čemu niži alkil, niži alkoksi i niži alkenil mogu opcijski biti supstituirani nižim alkoksikarbonilom, arilom ili heterociklilom;
Thus, the first interior guiding passage, extending longitudinally from the proximal open end of the flushing unit to the distal open end of the tubular member for sheathing at least a part of said first endoscopic instrument, is defined, cf. claim 1. 
Dakle, definiran je prvi unutarnji prolaz za vođenje, koji se prostire uzdužno od bližeg otvorenog kraja jedinice za ispiranje do udaljenijeg otvorenog kraja cijevnog elementa radi omatanja barem jednog dijela navedenog prvog endoskopskog instrumenta, usporedi patentni zahtjev 1.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein the metallic nanoparticle comprises a surface component enabling specific targeting of biological tissues or cells. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu nanočestica obuhvaća površinsku komponentu koja omogućuje specifično ciljanje bioloških tkiva ili stanica.
The compound or salt for use according to Claim 13, wherein the chemotherapy agent is selected from the group consisting of 5-fluorouracil, hydroxyurea, gemcitabine, methotrexate, pemetrexed, doxorubicin, etoposide, cisplatin, and taxol. 
Spoj, ili sol, namijenjeni upotrebi u skladu s patentnim zahtjevom 13, naznačen time što se kemoterapijsko sredstvo bira iz skupine koju čine 5-fluoruracil, hidroksiurea, gemcitabin, metotreksat, pemetreksed, doksorubicin, etopozid, cisplatin, te taksol.
Biomaterials as claimed in claim 3, wherein in the weight ratio is of 25:75. 
Biomaterijali kako su prijavljeni u patentnom zahtjevu 3, naznačeni time da maseni omjer jest 25:75.
Albumin Binding Peptide-Fab Compounds of the Invention: 
Datum podnošenja europske prijave patenta:
A pharmaceutical composition comprising a compound of the formula (2): and an aqueous buffer, wherein the composition has a pH of from about 5 to about 6. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 6, gdje farmaceutska kompozicija ima pH od oko 4.
brominating the product of step (a) with bromine in a compatible solvent; and further converting the product of said step(s) to (−)-halofenate. 
(b) bromiranje proizvoda iz koraka (a) bromom u kompatibilnom otapalu; i dalje konvertiranje proizvoda spomenutog/spomenutih koraka u (-)-halofenat, 20.
The production line according to claim 13, wherein the production line is a floor production line that comprises at least one of a squaring line, a square edging line, a framing line, a hot or cold pressing line, a sectioning line and a drilling line. 
Proizvodna linija prema bilo kojem od prethodnih zahtjeva, naznačena time što je to proizvodna linija za podove, a obuhvaća liniju za određivanje pravih kuteva, liniju za rezanje pravih kuteva, liniju za porubljivanje, liniju za vruće ili hladno prešanje, liniju za rezanje u dijelove ifili liniju za bušenje.
A compound of Formula I, or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof, wherein: 
Spoj Formule I, [image], ili njegova farmaceutski prihvatljiva sol, hidrat, solvat, enantimer ili stereoizomer, naznačen time što:
Kollidon™ CL crospovidone in an amount of about 4% by weight of the total composition; sodium lauryl sulfate in an amount of about 2% by weight of the total composition; 
Kollidon"M CL krospovidon u količini od oko 4 masenih % cjelokupnog pripravka; natrijev lauril sulfat u količini od oko 2 masenih % cjelokupnog pripravka;
The compound or pharmacologically acceptable salt thereof according to claim 1, 18, 20 or 21, wherein Het is a group represented by the formula: which may be substituted with 1 to 3 substituents selected from Substituent Group A4, wherein... represents a single bond or a double bond, X3 represents a methine group or methylene group, an imino group, an oxygen atom, a sulfur atom or -SO2-, which may be substituted with a substituent selected from Substituent Group A4, Y6 represents a carbon atom or a nitrogen atom, and na and nb independently represent an integer of 0 to 3. 
predstavlja jednostruku vezu ili dvostruku vezu, X3 predstavlja metinsku skupinu ili metilensku skupinu, imino skupinu, atoma kisika, atom sumpora ili -SO2-, koji se može supstituirati sa supstituentom odabranim iz skupine supstituenata A4, Y6 predstavlja atom ugljika ili atom dušika, a na i nb neovisno predstavljaju cijeli broj u rasponu od 0 do 3. Spoj ili njegova farmakološki prihvatljiva sol u skladu s patentnim zahtjevom 7, naznačen time, da je Het skupina prikazana formulom:
The therapeutic hosiery item according to one or more of the preceding claims, characterized in that said second rows of knitting (2) are composed of a double-coated elastomer yarn (2a). 
Terapeutska čarapa prema jednom ili više prethodnih zahtjeva, naznačena time, da su spomenuti parni redovi pletiva (2) izrađeni od dvostruko prevučenog elastomernog konca (2).
Packaging unit according to claim 9, wherein the label (86) further comprises a groove (84) through which an end of the protrusion protrudes in a closed position of the packaging unit. 
Jedinica za pakiranje prema zahtjevu 9, naznačena time da naljepnica (86) nadalje sadrži žljeb (84) kroz koji se kraj izbočine proteže u zatvorenom položaju jedinice pakiranja.
Crystallization of this mixture was achieved by pouring the product into vigorously stirred 10°C 85% EtOH/H2O (1.2L), After stirring for several hours, the crystals were collected by filtration, washed with cold 1:1 EtOH/H2O and dried under vacuum. 
Poslije mješanja od nekoliko sati, kristali su sakupljeni filtracijom, isprani hladnim 1:1 EFtOH/H,0 1 sušeni pod vakuumom.
A pharmaceutical preparation as defined in claim 5 for use in treating or reducing a disease including injury to central nervous system such as head trauma and spinal cord injury, cerebral infarction, ischemic heart diseases and peripheral arterial occlusive diseases, or after-effects of these diseases. 
Farmaceutski pripravak kako je definiran u zahtjevu 5 naznačen time da je za upotrebu za liječenje ili smanjenje bolesti, uključujući ozljede središnjeg živčanog sustava, kao što su trauma glave i ozljeda leđne moždine, moždani infarkt, ishemijske bolesti srca 1 bolesti začepljenja perifernih arterija, ili posljedica navedenih bolesti.
The method of claim 3, wherein the reaction system is separated by centrifugation after the alkali treatment and before the acid treatment, and the obtained heavy phase is optionally concentrated and/or dried prior to the acid treatment. 
Postupak prema zahtjevu 1 ili 2, naznačen time da reakcijski sustav nakon alkalnog tretmana i prije tretmana kiselinom centrifugiranjem bude odvojen i teška faza prije tretmana kiselinom bude opcionalno koncentrirana i / ili osušena.
The composition according to claim 1, wherein the calcium carbonate has a weight median particle diameter d 50 from 0.6 µm to 0.8 µm and preferably of 0.7 µm, measured according to the sedimentation method. 
Sastav prema zahtjevu 1, naznačen time da kalcij karbonat ima težinski medijan promjera čestice dsg od 0.6 um do 0.8 um te poželjno 0.7 um, mjereno prema sedimentacijskoj metodi.